FY2025 EPS Forecast for Oruka Therapeutics Cut by Analyst

Oruka Therapeutics, Inc. (NASDAQ:ORKA) – Equities researchers at Wedbush decreased their FY2025 earnings estimates for Oruka Therapeutics in a research report issued to clients and investors on Thursday, November 13th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings of ($1.90) per share for the year, down from their prior forecast of ($1.70). Wedbush currently has a “Outperform” rating and a $40.00 target price on the stock. The consensus estimate for Oruka Therapeutics’ current full-year earnings is ($3.41) per share. Wedbush also issued estimates for Oruka Therapeutics’ Q4 2025 earnings at ($0.49) EPS, Q1 2026 earnings at ($0.51) EPS, Q2 2026 earnings at ($0.54) EPS, Q3 2026 earnings at ($0.56) EPS, Q4 2026 earnings at ($0.53) EPS, FY2026 earnings at ($2.14) EPS, FY2027 earnings at ($2.46) EPS, FY2028 earnings at ($3.15) EPS and FY2029 earnings at ($3.79) EPS.

ORKA has been the subject of a number of other research reports. HC Wainwright reduced their price objective on Oruka Therapeutics from $45.00 to $40.00 and set a “buy” rating for the company in a research report on Monday, October 27th. Jefferies Financial Group started coverage on shares of Oruka Therapeutics in a research report on Thursday, November 13th. They issued a “buy” rating and a $45.00 price target for the company. Barclays started coverage on Oruka Therapeutics in a research note on Monday, October 13th. They issued an “overweight” rating and a $48.00 price objective for the company. Guggenheim began coverage on Oruka Therapeutics in a research note on Monday, October 27th. They set a “buy” rating and a $60.00 target price on the stock. Finally, Wall Street Zen downgraded Oruka Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Oruka Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $45.14.

Oruka Therapeutics Price Performance

NASDAQ ORKA opened at $27.45 on Monday. The stock has a market capitalization of $1.33 billion, a price-to-earnings ratio of -9.77 and a beta of -0.30. Oruka Therapeutics has a 1-year low of $5.49 and a 1-year high of $29.98. The business’s fifty day moving average price is $23.08 and its 200-day moving average price is $16.53.

Oruka Therapeutics (NASDAQ:ORKA) last issued its earnings results on Wednesday, November 12th. The company reported ($0.55) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.01.

Hedge Funds Weigh In On Oruka Therapeutics

Several institutional investors have recently added to or reduced their stakes in ORKA. PNC Financial Services Group Inc. purchased a new stake in shares of Oruka Therapeutics during the 3rd quarter worth approximately $39,000. Russell Investments Group Ltd. bought a new stake in Oruka Therapeutics in the third quarter worth $43,000. Legal & General Group Plc purchased a new stake in Oruka Therapeutics during the second quarter valued at $28,000. Ameritas Investment Partners Inc. purchased a new stake in Oruka Therapeutics during the second quarter valued at $31,000. Finally, BNP Paribas Financial Markets lifted its position in Oruka Therapeutics by 464.0% during the second quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock valued at $31,000 after purchasing an additional 2,306 shares during the last quarter. Hedge funds and other institutional investors own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.